User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

Primary tabs

download
  • Open access
  • PDF
  • 1.17 M
Moreno, Lucas Weston, Rebekah Owens, Cormac Valteau-Couanet, Dominique Gambart, Marion Brichard, Benedicte [UCL] Wheatley, Keith

Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic agent bevacizumab (B).

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2024
Language Anglais
Journal information "Journal of Clinical Oncology" - Vol. 42, no. 10, p. 1135-1145 (2024)
Peer reviewed yes
Publisher American Society of Clinical Oncology (ASCO)
issn 0732-183X
e-issn 1527-7755
Publication status Publié
Affiliation UCL - SSH/IACS - Institute of Analysis of Change in Contemporary and Historical Societies
Keywords n/a
Links
Bibliographic reference Moreno, Lucas ; Weston, Rebekah ; Owens, Cormac ; Valteau-Couanet, Dominique ; Gambart, Marion ; et. al. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. In: Journal of Clinical Oncology, Vol. 42, no. 10, p. 1135-1145 (2024)
Permanent URL http://hdl.handle.net/2078.1/298291